# US 2021/0079006 A1 · Nitrogen-containing heterocyclic compounds as fxr modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079006 A1
- Document ID: US20210079006A1
- Status: Published application
- Kind: A1
- Application number: 17/108,644
- Filed: 2020-12-01
- Published: 2021-03-18
- Earliest claimed: 2016-11-04
- Assignees: Hepagene Therapeutics (HK) Limited
- Applicants: Hepagene Therapeutics (HK) Limited
- Inventors: Xiaodong Xu
- Web page: https://patentgrep.com/patent/US20210079006A1

## CPC

- C07D 487/08: Bridged systems
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 413/14: containing three or more hetero rings
- C07D 417/14: containing three or more hetero rings
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present technology is directed to compounds, compositions, and methods related to modulation of FXR. In particular, the present compounds and compositions may be used to treat FXR-mediated disorders and conditions, including, e.g., liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, and atherosclerosis, and renal disease.

## Claims

### Claim 1

A compound according to formula I
stereoisomers, and/or salts thereof wherein
L and M are independently selected from N and CR7, provided that at least one of L and M is N;
Z is a substituted or unsubstituted C1-C4 alkylene group;
W is
X is
D is N or CR9;
G4 is CR13; G1, G2, G3 are selected from the group consisting of CH and CR11;
Q is O, S, or NR12;
R1 and R2 are independently H, OH, halo, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, or hydroxyalkyl group;
R3 is a substituted or unsubstituted alkyl or cycloalkyl group;
R4 is CN, SO3H, CONRaRb, SO2NRaRb, NHSO2Rb, SO2NHCORa, CO2Rc, or a substituted or unsubstituted tetrazolyl or 1,2,4-oxadiazol-5(4H)-one-3-yl group;
R7 is H, OH, halo, CN, carboxyl, amido, NRaRb, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, or aminoalkyl group;
R9 is H, halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group, or, when n is 2 or 3, two of the R10 groups together may be a substituted or unsubstituted C2-C5 alkylene, heteroalkylene, alkenylene or heteroalkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached;
R11 at each occurrence is independently OH, halo, CF3, CN, carboxyl, NRaRb, or a substituted or unsubstituted alkyl, alkoxy group, or phenyl group;
R12 is H or a substituted or unsubstituted C1-C6 alkyl group; and
R13 is halo, or a substituted or unsubstituted C1-C6 alkyl, or O—(C1-C6 alkyl) group;
Ra at each occurrence is independently H, or a substituted or unsubstituted alkyl, haloalkyl, cycloalkyl, aryl, or SO2-alkyl group;
Rb at each occurrence is H or a substituted or unsubstituted alkyl, or haloalkyl group;
Rc is H or a substituted or unsubstituted alkyl, alkenyl, alkynyl, or cycloalkyl group;
n is 0, 1, 2, 3, or 4; and
r and t are each independently 1, 2, or 3.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Z is an unsubstituted C1-C4 alkylene group.

### Claim 3 (depends on 2)

The compound of claim 2, wherein W is

### Claim 4 (depends on 3)

The compound of claim 3, wherein X is
wherein q is 0, 1, or 2.

### Claim 5 (depends on 4)

The compound of claim 4 according to Formula IA or Formula IB:
wherein
r is 1 or 2; and
t is 2.

### Claim 6 (depends on 5)

The compound of claim 5 according to Formula IA, wherein L is N.

### Claim 7 (depends on 6)

The compound of claim 6 wherein n is 2 or 3 and two of the R10 groups together are a substituted or unsubstituted C2-C5 alkylene, heteroalkylene, alkenylene or heteroalkenylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached.

### Claim 8 (depends on 7)

The compound of claim 7 wherein two of the R10 groups together are a substituted or unsubstituted C2-C5 alkylene group having 2 separate points of attachment to the same carbon or different carbons of the nitrogen containing ring to which it is attached.

### Claim 9 (depends on 5)

The compound of claim 5 according to formula IA, wherein L is CR7.

### Claim 10 (depends on 9)

The compound of claim 9, wherein n is 0.

### Claim 11 (depends on 9)

The compound of claim 9, wherein n is 1 or 2.

### Claim 12 (depends on 11)

The compound of claim 11 wherein R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group.

### Claim 13 (depends on 3)

The compound of claim 3 according to Formula IB, wherein M is CR7.

### Claim 14 (depends on 13)

The compound of claim 13, wherein n is 0.

### Claim 15 (depends on 13)

The compound of claim 13, wherein n is 1 or 2.

### Claim 16 (depends on 15)

The compound of claim 15 wherein R10 at each occurrence is independently halo, CO2Rc, or a substituted or unsubstituted alkyl, alkoxy, hydroxyalkyl, cycloalkyl, or fluorinated cycloalkyl group.

### Claim 17 (depends on 5)

The compound of claim 5, wherein R4 is CO2H, CN, CONH2, SO2NH2, or a substituted or unsubstituted CO2—C1-C6 alkyl, CO2—C3-C6 cycloalkyl, CONH—C1-C6 alkyl, CONH—C3-C6 cycloalkyl, NH—SO2—C1-C6 alkyl, or tetrazolyl group.

### Claim 18 (depends on 17)

The compound of claim 17, wherein R4 is CO2H, CONH2, or a tetrazolyl group.

### Claim 19 (depends on 5)

The compound of claim 5, wherein R1 and R2 are independently halo, CN, CO2Re, NReRf, or a substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy, or C1-C6 hydroxyalkyl group; and
wherein Re and Rf at each occurrence are independently H or a substituted or unsubstituted C1-C6 alkyl group.

### Claim 20 (depends on 19)

The compound of claim 19, wherein R1 and R2 are both Cl.

### Claim 21 (depends on 5)

The compound of claim 5, wherein R3 is a substituted or unsubstituted C1-C6 alkyl or C3-C6 cycloalkyl group.

### Claim 22 (depends on 5)

The compound of claim 5, wherein R3 is an isopropyl or cyclopropyl group.

### Claim 23 (depends on 5)

The compound of claim 5, wherein X is

### Claim 24 (depends on 23)

The compound of claim 23, wherein R11 at each occurrence is independently halo, CF3, or a substituted or unsubstituted alkyl, alkoxy, or phenyl group.

### Claim 25 (depends on 23)

The compound of claim 23, wherein R13 is F, or a substituted or unsubstituted C1-C3 alkyl, or O—(C1-C3 alkyl) group.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R13 is F, CH3, or O—CH3.

### Claim 27 (depends on 23)

The compound of claim 23, wherein q is 0.

### Claim 28

A compound selected from the group consisting of compounds II-17, II-30, II-36, II-37, II-38, II-39, II-43, II-44, II-45, I-46, II-47, II-48, II-49, I-50, II-51, III-08, IV-10, and VI-11.

### Claim 29 (depends on 1)

A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 30 (depends on 1)

A pharmaceutical composition comprising an effective amount of the compound of claim 1 for treating an FXR-mediated disorder or condition selected from the group consisting of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, and renal disease.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30 wherein the disorder or condition is a liver disease selected from the group consisting of primary biliary cirrhosis (PBC), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.

### Claim 32 (depends on 1)

A method of treatment comprising administering an effective amount of a compound of of claim 1, or administering a pharmaceutical composition comprising an effective amount of a compound of claim 1, to a subject suffering from an FXR-mediated disorder or condition selected from the group consisting of liver disease, hyperlipidemia, hypercholesteremia, obesity, metabolic syndrome, cardiovascular disease, gastrointestinal disease, atherosclerosis, and renal disease.

### Claim 33 (depends on 32)

The method of claim 32, wherein the disorder or condition is a liver disease selected from the group consisting of primary biliary cirrhosis (PB C), cerebrotendinous xanthomatosis (CTX), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), liver fibrosis, and liver cirrhosis.

### Claim 34 (depends on 1)

A method comprising modulating FXR by contacting FXR with an effective amount of a compound of claim 1.
